Pharmacologic treatments for covid-19 patients

Bamlanivimab (LY-CoV555) vs Placebo


Outpatients

Forest plots
(last update: 2022-02-25)

Summary of findings
(last update: 2022-03-09)

Hospitalized patients

Forest plots
(last update: 2022-03-09)

Summary of findings
(last update: 2022-03-14)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=138

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04518410
ACTIV-2/A5401
Chew K (A), medRxiv, 2021
Full text
Commentary
Commentary
Mixed

LY-CoV555 7000 mg

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA N=97
Some concerns
Details

Full description

NCT04518410
ACTIV-2/A5401
Chew K (B), medRxiv, 2021
Full text
Commentary
Commentary
Mixed

LY-CoV555 700 mg

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA N=222
Some concerns
Details

Full description

NCT04427501
BLAZE-1
Gottlieb R, JAMA, 2021
Full text
Commentary
Commentary
Private

LY-CoV555 700 mg

LY-CoV555 700 mg

LY-CoV555+LY-CoV016

Placebo

LY-CoV555+LY-CoV016

Placebo

RCT Outpatients with COVID-19 (mild ambulatory) treated at 49 centers in USA N=592
Some concerns
Details

Full description

NCT04501978
ACTIV-3/TICO
Lundgren J, J Ann Intern Med, 2021
Full text
Full text
Full text
Commentary
Commentary
Mixed

LY-CoV555

Placebo

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 31 centers in Denmark, Singapore and USA N=326
Some concerns
Details

Full description

NCT04427501
BLAZE-1
Chen P, N Engl J Med, 2020
Full text
Commentary
Private

LY-CoV555

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 41 centers in USA N=467
Low
Details

Full description